Related Experiment Video

Updated: Jun 12, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma

F Ballanger1, J M Nguyen, A Khammari

  • 1Department of Cancer Dermatology, INSERM U892, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, Nantes, France.

Dermatology (Basel, Switzerland)
|May 21, 2010
PubMed
Abstract

Insights

Bexarotene therapy did not alter T-cell clones in cutaneous T-cell lymphoma (CTCL) patients. However, detecting T-cell clones before treatment predicted disease progression, and UV therapy improved outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • The precise mechanisms of action for bexarotene, a retinoid therapy, remain incompletely elucidated.
  • Understanding bexarotene's effects on T-cell populations is crucial for optimizing cutaneous T-cell lymphoma (CTCL) treatment.

Purpose of the Study:

  • To investigate the impact of bexarotene on dominant T-cell clones in patients with CTCL.
  • To determine if T-cell clone evolution correlates with therapeutic response or disease progression.
  • To assess the combined effect of bexarotene and phototherapy on T-cell clones and clinical outcomes.

Main Methods:

  • A retrospective analysis was conducted on 35 CTCL patients treated with bexarotene.
  • T-cell clones were monitored in peripheral blood and skin samples.
  • Patients received bexarotene (300 mg/m(2)) for over 3 months, with 7 patients also receiving phototherapy.

Main Results:

  • No significant changes in T-cell clone populations were observed in either skin or peripheral blood during bexarotene treatment.
  • Pre-treatment detection of T-cell clones in peripheral blood was significantly associated with disease progression.
  • Combination therapy with bexarotene and UV therapy demonstrated improved therapeutic response, independent of T-cell clone dynamics.

Conclusions:

  • This study provides novel insights into the evolution of T-cell clones during bexarotene therapy in CTCL.
  • Bexarotene's efficacy may not be directly mediated by altering dominant T-cell clones.
  • The combination of bexarotene with UV therapy warrants further investigation for enhanced CTCL treatment outcomes.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...